Akoya Biosciences, Inc.(AKYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AKYA Akoya Biosciences, Inc.

Halted 07-07 16:00:00 EDT

1.29

+0.00

0.00%

High1.29	Low1.29	Vol0.00
Open1.29	D1 Closing1.29	Amplitude0.00%
Mkt Cap64.44M	Tradable Cap16.27M	Total Shares49.95M
T/O996.14K	T/O Rate0.00%	Tradable Shares12.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AKYA","market":"US","secType":"STK","nameCN":"Akoya Biosciences, Inc.","latestPrice":1.29,"timestamp":1751918400000,"preClose":1.29,"halted":3,"volume":0,"delay":0,"floatShares":12608847,"shares":49954210,"eps":-0.959533,"marketStatus":"Halted","change":0,"latestTime":"07-07 16:00:00 EDT","open":1.29,"high":1.29,"low":1.29,"amount":996141.0447768001,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.959533,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":1.29,"volumeRatio":0},"requestUrl":"/m/hq/s/AKYA","defaultTab":"news","newsList":[{"id":"2571296336","title":"Carlsmed Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary Amid Leadership Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2571296336","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571296336?lang=en_us&edition=fundamental","pubTime":"2025-09-29 21:01","pubTimestamp":1759150881,"startTime":"0","endTime":"0","summary":"Carlsmed Inc. has appointed Jennifer Kamocsay as Chief Legal Officer and Secretary, effective immediately. Kamocsay brings over 20 years of experience in corporate legal roles at companies including Akoya Biosciences, Rubius Therapeutics, and Progress Software Corporation. She will oversee legal counsel, compliance, and corporate governance for the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carlsmed Inc. published the original content used to generate this news brief via GlobeNewswire  on September 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL5Mbxg0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","AKYA","IE00BKPKM429.USD","NDAQ","IE00B3QW5Z07.USD","BK4588","LU2210150020.SGD","BK4082","LU2065732104.USD","CARL","IE00BGHQF748.EUR","BK4097","LU2210149790.SGD","BK4112","LU0314104364.USD","LU2095319765.USD","BK4121","PRGS","BK4539","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2569745180","title":"Quanterix Corporation Issues Amendment to Financial Report Following Merger with Akoya Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2569745180","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569745180?lang=en_us&edition=fundamental","pubTime":"2025-09-24 04:07","pubTimestamp":1758658040,"startTime":"0","endTime":"0","summary":"Quanterix Corporation has issued an amendment to its Current Report  following the completion of a merger with Akoya Biosciences, Inc. on July 8, 2025. The amendment provides unaudited pro forma condensed combined financial information, reclassifying certain financial items to align with Quanterix's presentation. These adjustments include reclassifications of interest expense, amortization of capitalized software costs, and changes in the fair value of contingent consideration. The report clarifies that the pro forma data is not necessarily indicative of actual or future financial outcomes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via EDGAR, the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL8nS21g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTRX","BK4121","BK4539","AKYA"],"gpt_icon":0},{"id":"2557919015","title":"Quanterix Q2 revenue falls 29%, net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2557919015","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557919015?lang=en_us&edition=fundamental","pubTime":"2025-08-08 05:00","pubTimestamp":1754600409,"startTime":"0","endTime":"0","summary":"Quanterix Q2 revenue falls 29%, net loss widensOverviewQuanterix Q2 2025 revenue falls 29% yr/yr, net loss widens significantlyCompany completed acquisition of Akoya Biosciences, aiming for cash flow ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLX21C897:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKYA","QTRX"],"gpt_icon":0},{"id":"2557159918","title":"Quanterix Reports Q2 Net Loss of $30M, Alzheimer's Diagnostics Revenues More Than Tripled Year-Over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2557159918","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557159918?lang=en_us&edition=fundamental","pubTime":"2025-08-08 04:26","pubTimestamp":1754598378,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire  on August 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL3MQmmY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTRX","AKYA"],"gpt_icon":0},{"id":"2554335927","title":"Quanterix Corporation Announces Workforce Reduction Plan to Save $18 Million Annually Following Akoya Biosciences Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2554335927","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554335927?lang=en_us&edition=fundamental","pubTime":"2025-07-25 04:31","pubTimestamp":1753389107,"startTime":"0","endTime":"0","summary":"Quanterix Corporation Announces Workforce Reduction Plan to Save $18 Million Annually Following Akoya Biosciences Acquisition. Quanterix Corporation has announced a corporate reorganization plan aimed at reducing operating costs and preserving cash following its acquisition of Akoya Biosciences, Inc. The reorganization includes a series of headcount reductions expected to be largely completed by the third quarter of 2025, with anticipated annualized cash savings of approximately $18 million. To implement these changes, the company expects to incur expenses of around $2.5 million in severance, mostly occurring in 2025. These measures are part of the company's strategy to integrate operations and achieve the expected synergies and benefits from the acquisition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL2rN0Dk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTRX","BK4539","AKYA","BK4121"],"gpt_icon":0},{"id":"2552849082","title":"Quanterix Corporation Announces Executive Terminations at Akoya Biosciences in Cost-Saving Reorganization Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2552849082","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552849082?lang=en_us&edition=fundamental","pubTime":"2025-07-19 04:31","pubTimestamp":1752870684,"startTime":"0","endTime":"0","summary":"Quanterix Corporation has announced a reorganization plan involving the termination of certain executives from its newly acquired subsidiary, Akoya Biosciences, Inc. This move is part of the company's integration strategy aimed at achieving anticipated synergies and reducing costs. The reorganization is expected to lead to annual cash savings of approximately $2.8 million. However, Quanterix anticipates incurring expenses of around $3.3 million in 2025, primarily for severance payments under Akoya's Executive Severance Plan. The company cautions that actual results may vary, and additional charges might arise as the plan is executed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content use","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL89gzNn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTRX","BK4539","AKYA","BK4121"],"gpt_icon":0},{"id":"2550961787","title":"Quanterix Corporation Announces Inducement Grants of Restricted Stock Units to New Employees Following Akoya Biosciences Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2550961787","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550961787?lang=en_us&edition=fundamental","pubTime":"2025-07-12 05:00","pubTimestamp":1752267612,"startTime":"0","endTime":"0","summary":"Quanterix Corporation Announces Inducement Grants of Restricted Stock Units to New Employees Following Akoya Biosciences Acquisition. BILLERICA, Mass.---- Quanterix Corporation  has announced the approval of inducement grants of restricted stock units  for 267,269 shares of its common stock, awarded to twenty newly-hired employees following the acquisition of Akoya Biosciences, Inc. These equity awards are part of the employees' compensation package and are intended to incentivize their acceptance of employment with Quanterix. The RSUs will vest in full one year from the grant date, contingent upon the employees' ongoing employment with the company or its subsidiaries. The grants were made under the Nasdaq Rule 5635 inducement grant exception.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nNDL1LNXJ7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","QTRX","BK4121","AKYA"],"gpt_icon":0},{"id":"2549097547","title":"Quanterix Corporation Announces New Board Members as Mendel and Lai-Goldman Join Leadership Team Following Akoya Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2549097547","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549097547?lang=en_us&edition=fundamental","pubTime":"2025-07-08 21:07","pubTimestamp":1751980033,"startTime":"0","endTime":"0","summary":"Quanterix Corporation has announced changes to its Board of Directors following the acquisition of Akoya Biosciences. Scott Mendel and Myla Lai-Goldman, MD, have been appointed to the board, replacing Martin D. Madaus, PhD, and Sarah Hlavinka. Masoud Toloue will continue as Chief Executive Officer, and Vandana Sriram will remain as Chief Financial Officer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire  on July 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL2dBtnk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","QTRX","BK4539","AKYA"],"gpt_icon":0},{"id":"2549355771","title":"Akoya Biosciences Inc. Conducted Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2549355771","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549355771?lang=en_us&edition=fundamental","pubTime":"2025-07-08 04:05","pubTimestamp":1751918707,"startTime":"0","endTime":"0","summary":"Akoya Biosciences Inc. held a special meeting of stockholders on July 7, 2025. Stockholders approved the proposal to adopt the Amended and Restated Agreement and Plan of Merger involving Quanterix Corporation, Wellfleet Merger Sub, Inc., and Akoya Biosciences, Inc. Additionally, stockholders approved the proposal to adjourn the meeting if necessary to solicit additional proxies for the merger proposal. However, since the merger proposal was approved, the meeting was not adjourned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akoya Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commiss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nNDLc9FPkQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","AKYA","QTRX","BK4121"],"gpt_icon":0},{"id":"2540713820","title":"Akoya Biosciences Receives Unsolicited Acquisition Proposal Amid Merger Talks with Quanterix","url":"https://stock-news.laohu8.com/highlight/detail?id=2540713820","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540713820?lang=en_us&edition=fundamental","pubTime":"2025-06-03 04:06","pubTimestamp":1748894760,"startTime":"0","endTime":"0","summary":"Akoya Biosciences Inc. announced that it received an unsolicited acquisition proposal from a third party, referred to as Party A, to acquire the company in an all-cash tender offer. The proposal offers Akoya shareholders $1.40 per share in cash. This development follows Akoya's earlier agreement to merge with Quanterix Corporation, under which Akoya would become a wholly owned subsidiary of Quanterix. Akoya's board, after consulting with financial and legal advisors, has determined that the unsolicited proposal could potentially lead to a superior offer and is therefore engaging in discussions with Party A to explore the proposal further.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akoya Biosciences Inc. published the original conte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL3kzlCY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","QTRX","BK4121","AKYA"],"gpt_icon":0},{"id":"2537955953","title":"Akoya Shares Gain on Unsolicited Third-Party Acquisition Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2537955953","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537955953?lang=en_us&edition=fundamental","pubTime":"2025-05-22 02:45","pubTimestamp":1747853100,"startTime":"0","endTime":"0","summary":"Shares of Akoya Biosciences rose after the developer of medical imaging tools said it was considering a third party's bid instead of the previously announced buyout by Quanterix.Akoya stock climbed 26%, to $1.34, midday Wednesday. It is still down 42% this year.The Marlborough, Mass., company said it had received an unsolicited acquisition proposal on Tuesday offering to buy it in an all-cash deal. Under the terms of the proposed deal, each Akoya share would be exchanged for $1.40.Earlier this year, Akoya agreed to merge with Quanterix, which offered to pay Akoya shareholders 38 cents for a share and 0.1461 shares of Quanterix common stock. Quanterix shares declined 4%, to $4.77, on Wednesday.Akoya is reviewing and considering the new proposal. It said the deal could be considered a superior proposal, meaning it would be inconsistent with the company's fiduciary duties if Akoya didn't engage in discussions with the third party.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","AKYA","QTRX","BK4121"],"gpt_icon":0},{"id":"2537539609","title":"Sector Update: Health Care Stocks Slide Wednesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2537539609","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537539609?lang=en_us&edition=fundamental","pubTime":"2025-05-22 01:56","pubTimestamp":1747850190,"startTime":"0","endTime":"0","summary":"Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index falling 1% and the Health Care Select Sector SPDR Fund  dropping 1.3%.The iShares Biotechnology ETF  slumped 1.6%.In corporate news, UnitedHealth  allegedly paid thousands of dollars in bonuses to nursing homes where it installed its own medical teams and pressured them to help cut care expenses for residents, The Guardian reported. UnitedHealth shares were falling 5%.UroGen Pharma  shares tumbled 47% after it said its UGN-102 bladder cancer drug failed to receive the backing of a US Food and Drug Administration advisory committee.Akoya Biosciences  shares jumped 25% after it said in a Wednesday filing that it received an unsolicited acquisition proposal from an undisclosed third party, which offered $1.40 in cash for each Akoya common share.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0094547139.USD","LU1066051498.USD","IBB","LU2461242641.AUD","LU0345770308.USD","LU1323610961.USD","LU2125154935.USD","IE00BKVL7J92.USD","LU1035773651.USD","IE0002141913.USD","LU0320765059.SGD","LU0077335932.USD","LU0545039389.USD","AKYA","LU1551013342.USD","LU0211326755.USD","LU0048584097.USD","SGXZ99366536.SGD","LU1119994496.HKD","LU2089984988.USD","IE00B19Z9P08.USD","LU1084165304.USD","LU0211327993.USD","LU1934455863.HKD","LU0187121727.USD","URGN","LU2362541513.USD","LU0289739699.SGD","LU2111349929.HKD","LU1551013425.SGD","SGXZ51526630.SGD","IE0002270589.USD","LU0316494557.USD","LU1674673428.USD","BK4154","LU1732799900.SGD","LU0553294199.USD","LU2357305700.SGD","BK4588","BK4532","IE00B19Z8W00.USD","LU0738911758.USD","LU2361044865.SGD","LU0251132253.USD","LU0661504455.SGD","LU0965509101.SGD","UNH","XLV","IE00BWXC8680.SGD","LU1267930227.SGD"],"gpt_icon":1},{"id":"2537593206","title":"Akoya Biosciences Receives Unsolicited Buyout Offer From Third Party","url":"https://stock-news.laohu8.com/highlight/detail?id=2537593206","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537593206?lang=en_us&edition=fundamental","pubTime":"2025-05-21 23:45","pubTimestamp":1747842319,"startTime":"0","endTime":"0","summary":"Akoya Biosciences (AKYA) said in a Wednesday filing that it received an unsolicited acquisition proposal from an undisclosed third party, which offered $1.40 in cash for each Akoya common share.The co","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QTRX","BK4539","AKYA","BK4121"],"gpt_icon":0},{"id":"2537982767","title":"BRIEF-Akoya Biosciences Inc - On May 20, Receives Unsolicited Acquisition Proposal At $1.40 Per Share From A Third Party- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537982767","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537982767?lang=en_us&edition=fundamental","pubTime":"2025-05-21 19:16","pubTimestamp":1747826198,"startTime":"0","endTime":"0","summary":"BRIEF-Akoya Biosciences Inc - On May 20, Receives Unsolicited Acquisition Proposal At $1.40 Per Share From A Third Party- SEC FilingMay 21  - Akoya Biosciences Inc AKYA.O:AKOYA BIOSCIENCES INC - ON MAY 20, RECEIVES UNSOLICITED ACQUISITION PROPOSAL AT $1.40 PER SHARE FROM A THIRD PARTY- SEC FILINGAKOYA BIOSCIENCES INC - BOARD CONSIDERS UNSOLICITED PROPOSAL AS POTENTIAL SUPERIOR OFFER - SEC FILINGSource text: [ID:n0001558370-25-008039]Further company coverage: AKYA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nFWN3RS2OL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4539","AKYA"],"gpt_icon":0},{"id":"2537236989","title":"Akoya Biosciences Receives Unsolicited Acquisition Proposal Amid Ongoing Merger Discussions with Quanterix","url":"https://stock-news.laohu8.com/highlight/detail?id=2537236989","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537236989?lang=en_us&edition=fundamental","pubTime":"2025-05-21 18:02","pubTimestamp":1747821761,"startTime":"0","endTime":"0","summary":"Akoya Biosciences Inc. recently announced an update regarding its merger activities. On April 28, 2025, the company entered into an Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and its subsidiary, Wellfleet Merger Sub, Inc. Under this agreement, Wellfleet Merger Sub will merge with and into Akoya, making Akoya a wholly owned subsidiary of Quanterix. Additionally, on May 20, 2025, Akoya disclosed it had received an unsolicited acquisition proposal from a third party, offering an all-cash transaction where each share of Akoya common stock would be exchanged for $1.40. Akoya's board is currently reviewing this proposal to determine if it could lead to a superior offer compared to the current merger agreement with Quanterix.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL4l89Df:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4539","QTRX","AKYA"],"gpt_icon":0},{"id":"2536356456","title":"Akoya Biosciences Is Maintained at Hold by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2536356456","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536356456?lang=en_us&edition=fundamental","pubTime":"2025-05-19 23:24","pubTimestamp":1747668240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AKYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 19, 2025 11:24 ET (15:24 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4121","AKYA"],"gpt_icon":0},{"id":"2535875927","title":"Akoya Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535875927","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535875927?lang=en_us&edition=fundamental","pubTime":"2025-05-13 05:02","pubTimestamp":1747083739,"startTime":"0","endTime":"0","summary":"Akoya Biosciences Inc reports results for the quarter ended March 31 - Earnings SummaryAkoya Biosciences Inc AKYA.OQ reported a quarterly adjusted loss of 32 cents per share for the quarter ended Marc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nL8N3RK2TG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKYA"],"gpt_icon":0},{"id":"2535782879","title":"Akoya Biosciences Q1 EPS $(0.32) Misses $(0.20) Estimate, Sales $16.64M Miss $19.95M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535782879","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535782879?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:43","pubTimestamp":1747082581,"startTime":"0","endTime":"0","summary":"Akoya Biosciences (NASDAQ:AKYA) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.20) by 60 percent. This is a 33.33 percent increase over losses of $(0.48) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45361211/akoya-biosciences-q1-eps-0-32-misses-0-20-estimate-sales-16-64m-miss-19-95m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKYA"],"gpt_icon":0},{"id":"2535781385","title":"Akoya Biosciences Reports 37.9% Improvement in Operating Loss for Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2535781385","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535781385?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:11","pubTimestamp":1747080663,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akoya Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nNDL7tPq8s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKYA","QTRX"],"gpt_icon":0},{"id":"2535789258","title":"BRIEF-Akoya Biosciences Q1 Gross Margin 59.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535789258","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535789258?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:05","pubTimestamp":1747080348,"startTime":"0","endTime":"0","summary":"BRIEF-Akoya Biosciences Q1 Gross Margin 59.3%\n\n\nMay 12 (Reuters) - Akoya Biosciences Q1 revenue USD 16.6 million vs. IBES estimate USD 19.9 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nPLX2BB1F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4539","AKYA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akoyabio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0.0238},{"period":"1year","weight":-0.4941},{"period":"ytd","weight":-0.4367}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.05841},{"month":2,"riseRate":0.5,"avgChangeRate":-0.077905},{"month":3,"riseRate":0,"avgChangeRate":-0.157209},{"month":4,"riseRate":0,"avgChangeRate":-0.153776},{"month":5,"riseRate":0.4,"avgChangeRate":-0.084149},{"month":6,"riseRate":0.8,"avgChangeRate":0.09458},{"month":7,"riseRate":0.4,"avgChangeRate":-0.005227},{"month":8,"riseRate":0.25,"avgChangeRate":-0.120834},{"month":9,"riseRate":0.5,"avgChangeRate":-0.033565},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023258},{"month":11,"riseRate":0.25,"avgChangeRate":-0.010141},{"month":12,"riseRate":0.75,"avgChangeRate":0.01733}],"exchange":"NASDAQ","name":"Akoya Biosciences, Inc.","nameEN":"Akoya Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Akoya Biosciences, Inc.(AKYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Akoya Biosciences, Inc.(AKYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Akoya Biosciences, Inc.,AKYA,Akoya Biosciences, Inc.股票,Akoya Biosciences, Inc.股票老虎,Akoya Biosciences, Inc.股票老虎国际,Akoya Biosciences, Inc.行情,Akoya Biosciences, Inc.股票行情,Akoya Biosciences, Inc.股价,Akoya Biosciences, Inc.股市,Akoya Biosciences, Inc.股票价格,Akoya Biosciences, Inc.股票交易,Akoya Biosciences, Inc.股票购买,Akoya Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Akoya Biosciences, Inc.(AKYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Akoya Biosciences, Inc.(AKYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction